diff --git a/openprescribing/common/measure_tags.json b/openprescribing/common/measure_tags.json index 16f59e7a0d..758c63e4ea 100644 --- a/openprescribing/common/measure_tags.json +++ b/openprescribing/common/measure_tags.json @@ -77,7 +77,7 @@ }, "opportunities": { "name": "National medicines optimisation opportunities", - "description": "These measures show areas related to the NHS England national medicines optimisation opportunities for 2023-2024." + "description": "These measures show areas related to the NHS England national medicines optimisation opportunities for 2024-2025." }, "pain": { "name": "Pain", diff --git a/openprescribing/measures/definitions/amox_500_15_caps.json b/openprescribing/measures/definitions/amox_500_15_caps.json index f8826393d2..d3665102df 100644 --- a/openprescribing/measures/definitions/amox_500_15_caps.json +++ b/openprescribing/measures/definitions/amox_500_15_caps.json @@ -11,8 +11,8 @@ " 500mg three times a day for 5 days. ", "Where greater than 5 days treatment is prescribed for these indications, this increases both the unnecessary prescribing of antibiotics, as well as cost.", " There are however some indications which require higher doses/longer durations of amoxicillin for example, treatment of H. pylori.

", - "

NHS England National Medicines Optimisation Opportunities for 2023/24", - "identify use of the shortest effective antibiotic courses as an area for improvement, and suggests that 75% of amoxicillin prescriptions should be 5-day courses by March 2024." + "

NHS England National Medicines Optimisation Opportunities for 2024/25", + "identify use of the shortest effective antibiotic courses as an area for improvement, and suggests that 60% of amoxicillin prescriptions should be 5-day courses by March 2025." ], "tags": [ "antimicrobial", diff --git a/openprescribing/measures/definitions/carbon_salbutamol.json b/openprescribing/measures/definitions/carbon_salbutamol.json index cb9643efa6..feabeac0f3 100644 --- a/openprescribing/measures/definitions/carbon_salbutamol.json +++ b/openprescribing/measures/definitions/carbon_salbutamol.json @@ -10,7 +10,7 @@ "committed to reducing its carbon footprint by 80% by 2028 to 2032, including a shift to lower carbon inhalers.

", "

Salbutamol metered dose inhalers (MDIs) are the single biggest source of carbon emissions from NHS medicines prescribing.

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify reducing carbon emissions from inhalers as an area for improvement.

", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify reducing carbon emissions from inhalers as an area for improvement.

", "

Data on carbon emissions per salbutamol inhaler can be viewed in the ", "", "table here.

" diff --git a/openprescribing/measures/definitions/doxy_100_6_qty.json b/openprescribing/measures/definitions/doxy_100_6_qty.json index 9ec0b53cc3..05ebd43f68 100644 --- a/openprescribing/measures/definitions/doxy_100_6_qty.json +++ b/openprescribing/measures/definitions/doxy_100_6_qty.json @@ -12,7 +12,7 @@ "For doxycycline this would be 200mg on the first day, then 100mg once a day for 4 days (5-day course in total) requiring a total of 6 capsules/dispersible tablets. ", "Where greater than 5 days treatment is prescribed for these indications, this increases both the unnecessary exposure to antibiotics, as well as cost. ", "There are some indications which require higher doses/longer durations of doxycycline, e.g. treatment of infected leg ulcers.

", - "

NHS England National Medicines Optimisation Opportunities for 2023/24", + "

NHS England National Medicines Optimisation Opportunities for 2024/25", "identify use of the shortest effective antibiotic courses as an area for improvement." ], "tags": [ @@ -41,4 +41,4 @@ "next_review": "2025-09-11", "measure_complexity": "low" } - \ No newline at end of file + diff --git a/openprescribing/measures/definitions/edoxaban.json b/openprescribing/measures/definitions/edoxaban.json index 2563525912..b70b3f8492 100644 --- a/openprescribing/measures/definitions/edoxaban.json +++ b/openprescribing/measures/definitions/edoxaban.json @@ -53,7 +53,7 @@ "", "

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify using best value direct-acting oral anticoagulants as an area for improvement.

", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify using best value direct-acting oral anticoagulants as an area for improvement.

", "

Please note: OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' ", "and therefore in this case we show the proportion of DOACs which are NOT prescribed as edoxaban or generic apixaban." ], diff --git a/openprescribing/measures/definitions/environmental_inhalers.json b/openprescribing/measures/definitions/environmental_inhalers.json index 143c74a618..4bb393e5d6 100644 --- a/openprescribing/measures/definitions/environmental_inhalers.json +++ b/openprescribing/measures/definitions/environmental_inhalers.json @@ -10,7 +10,7 @@ "including a shift to lower carbon inhalers. Dry powder inhalers (DPIs) and other newer types of inhalers like soft ", "mist inhalers are less harmful to the environment than traditional metered dose inhalers (MDIs).

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify reducing carbon emissions from inhalers as an area for improvement.

", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify reducing carbon emissions from inhalers as an area for improvement.

", "

NICE has ", "produced a inhaler decision aid to facilitiate discussion about inhaler options.

" ], diff --git a/openprescribing/measures/definitions/nhse_bgts.json b/openprescribing/measures/definitions/nhse_bgts.json index 34592ebc3c..0cf5dded05 100644 --- a/openprescribing/measures/definitions/nhse_bgts.json +++ b/openprescribing/measures/definitions/nhse_bgts.json @@ -11,7 +11,7 @@ "

In April 2023 NHS England published ", "commissioning guidelines, recommending specific meters, test strips and lancets.

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify promoting uptake of best value testing strips as an area for improvement.

", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify promoting uptake of best value testing strips as an area for improvement.

", "Please note: OpenPrescribing.net measures also have a consistent way of visualising measures, where 'lower is better', and therefore in this case we show the proportion of prescriptions for strips ", "which are NOT in the NHS commissioning recommendations.

" ], diff --git a/openprescribing/measures/definitions/nhse_lancets.json b/openprescribing/measures/definitions/nhse_lancets.json index f7006fa774..e38612b0a0 100644 --- a/openprescribing/measures/definitions/nhse_lancets.json +++ b/openprescribing/measures/definitions/nhse_lancets.json @@ -10,6 +10,8 @@ "Users use a “lancet” in order to prick their finger to draw a drop of blood for use with the meter. These lancets fit specific lancing devices, and are only used once.

", "In April 2023 NHS England published ", "commissioning guidelines, recommending specific meters, test strips and lancets.

", + "

The ", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify promoting uptake of best value testing strips as an area for improvement.

", "Please note: OpenPrescribing.net measures also have a consistent way of visualising measures, where 'lower is better', and therefore in this case we show the proportion of lancets ", "which are NOT in the NHS commissioning recommendations.

" ], diff --git a/openprescribing/measures/definitions/opioidome.json b/openprescribing/measures/definitions/opioidome.json index 8ea966c5f3..db90755a74 100644 --- a/openprescribing/measures/definitions/opioidome.json +++ b/openprescribing/measures/definitions/opioidome.json @@ -11,7 +11,7 @@ "and the risk of harm increases significantly above 120mg morphine ", "(or equivalent) per day, without much increase in benefit. ", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

", + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

", "

This measure describes the total Oral Morphine Equivalence (OME) in ALL opioid prescribing (excluding prescribing for addiction) ", "including low-dose opioids in drugs such as co-codamol and co-dydramol. This measure is experimental and should be used ", "with caution, as OME conversions vary in different reference sources. We have amended the measure to take into account changes in equivalency ", diff --git a/openprescribing/measures/definitions/opioidper1000.json b/openprescribing/measures/definitions/opioidper1000.json index 69b659c9e7..4ea6919bc8 100644 --- a/openprescribing/measures/definitions/opioidper1000.json +++ b/openprescribing/measures/definitions/opioidper1000.json @@ -19,7 +19,7 @@ "the updated August 2020 ", "tables available from the Faculty of Pain Medicine, Royal College of Anaesthetists.

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

" + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

" ], "tags": [ "core", diff --git a/openprescribing/measures/definitions/opioidspercent.json b/openprescribing/measures/definitions/opioidspercent.json index e78e4f8445..c07d7ae30f 100644 --- a/openprescribing/measures/definitions/opioidspercent.json +++ b/openprescribing/measures/definitions/opioidspercent.json @@ -19,7 +19,7 @@ "the updated August 2020 ", "tables available from the Faculty of Pain Medicine, Royal College of Anaesthetists.

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

" + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify reducing opioid use in chronic non-cancer pain as an area for improvement.

" ], "tags": [ "core", diff --git a/openprescribing/measures/definitions/saba.json b/openprescribing/measures/definitions/saba.json index 73d043eeb5..1c01ad938a 100644 --- a/openprescribing/measures/definitions/saba.json +++ b/openprescribing/measures/definitions/saba.json @@ -10,7 +10,7 @@ "reports that high use of short acting beta agonists (salbutamol and terbutaline) and poor adherence to ", "inhaled corticosteroids in asthma suggests poor control - these patients should be reviewed regularly to ensure good control.

", "

The ", - "NHS England National Medicines Optimisation Opportunities for 2023/24 identify improving patient outcomes from the use of inhalers as an area for improvement.

" + "NHS England National Medicines Optimisation Opportunities for 2024/25 identify improving patient outcomes from the use of inhalers as an area for improvement.

" ], "tags": [ "core",